The physicians at St. Elizabeth Healthcare are committed to providing the best and most current medical care for all patients. Through this commitment, our patients are eligible for participation in research trials sponsored by the National Cancer Institute and members of the Coalition of Cancer Cooperative Groups.
For questions/additional information about clinical research trials, please contact:
Darla Hehman, BSN, RN, CCRC
Oncology Research Nurse
Phone: (859) 301-5473
Fax: (859) 301-2607
Kim Schmidt, MSN, RN
Oncology Research Nurse
phone (859) 301-9418
fax (859) 301-2607
Listed below are all of the clinical research trials that are open to patients at St. Elizabeth Healthcare.
ECOG-2108 A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Women with Metastatic Breast Cancer
CALGB-40903 Phase II Study Neoadjuvant Letrozole for Postmenopausal Women with Estrogen Receptor Positive Ductal Carcinoma in SITU (DCIS)
ACOSOG-Z11102 Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC)
S1007 - A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone-responsive and Her2-Negative Breast Cancer according to Recurrence Score (RS)
GOG-0225 Can Diet and Physical Activity Modulate Ovarian or Primary Peritoneal Cancer Progression-Free Survival? (Sponsor: Gynecologic Oncology Group)
This randomized phase III trial is studying diet and physical activity changes to see how well they work compared with usual care in improving progression-free survival of patients with previously treated stage II, stage III, or stage IV ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
GOG-0235 A Prospective, Longitudinal Study of YKL-40 in Patients with FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Undergoing Primary Chemotherapy (Sponsor: Gynecologic Oncology Group)
This laboratory study is assessing tumor marker YKL-40 in patients with newly diagnosed stage III or stage IV ovarian epithelial cancer, primary peritoneal cavity cancer, or fallopian tube cancer undergoing chemotherapy.
GOG-0241 A GCIG Intergroup Mulitcenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- Bevacizumab Compared with Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients with Mucinous Epithelial Ovarian Cancer (MEOC) (Sponsor: Gynecologic Oncology Group)
This randomized phase III trial is studying oxaliplatin/capcetibine chemotherapy with or without bevacizumab to see how well it works compared with standard platinum/taxane chemotherapy with or without bevacizumab in treating patients with newly diagnosed or recurrent (and never treated with chemotherapy) mucinous ovarian or fallopian tube cancer.
GOG-0273 Chemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (Sponsor: Gynecologic Oncology Group)
This trial studies the chemotherapy toxicity on quality of life in patients age >70 years with stage I, stage II, stage III, or stage IV ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer.
GOG-0238 A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-only Recurrence of Carcinoma of the Uterine Corpus (Sponsor: Gynecologic Oncology Group)
This randomized phase II trial is studying radiation therapy and cisplatin to see how well they work compared with radiation therapy alone in treating patients with recurrent endometrial cancer.
GOG-0258 A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma (Sponsor: Gynecologic Oncology Group)
This randomized phase III trial studies combining pelvic radiation therapy with chemotherapy to see how well it works compared with standard chemotherapy alone in treating patients with advanced endometrial cancer.
GOG-0275 A Phase III Randomized Trial of Pulse Actinomcyin-D versus Multi-day Methotrexate for the Management of Low Risk Gestational Trophoblastic Neoplasia (Sponsor: Gynecologic Oncology Group)
This randomized phase III trial is studying the effectiveness of two standard types of chemotherapy treatment and explores factors that may influence quality of life in patients diagnosed with low-risk gestational trophoblastic neoplasia.
We encourage patients to explore additional information about clinical trials provided by the National Cancer Institute
or the American Cancer Society
. A current source for searching clinical trial information is provided by the Coalition of Cancer Cooperative Groups
Click on the NIH Clinical Research Trials and You
link for information about the risks and benefits of taking part in a clinical trial, how to find a trial, and questions to ask when considering participation in a trial.